{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:25:43Z","timestamp":1788819943847,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:00:00Z","timestamp":1598140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:00:00Z","timestamp":1598140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1208\/s12248-020-00495-4","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T16:02:24Z","timestamp":1598198544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products"],"prefix":"10.1208","volume":"22","author":[{"given":"Ioannis","family":"Loisios-Konstantinidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitava","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chiann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,23]]},"reference":[{"key":"495_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"key":"495_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","volume":"62","author":"T Loftsson","year":"2010","unstructured":"Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607\u201321.","journal-title":"J Pharm Pharmacol"},{"key":"495_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ejpb.2018.03.002","volume":"127","author":"M Grimm","year":"2018","unstructured":"Grimm M, Koziolek M, K\u00fchn JP, Weitschies W. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. Eur J Pharm Biopharm. 2018;127:309\u201317.","journal-title":"Eur J Pharm Biopharm"},{"key":"495_CR4","unstructured":"U.S. Food & Drug Administration (FDA). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA \u2014 Guidance for Industry. 2013. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioequivalence-Studies-With-Pharmacokinetic-Endpoints-for-Drugs-Submitted-Under-an-Abbreviated-New-Drug-Application.pdf. Accessed 03 March 2020."},{"key":"495_CR5","unstructured":"U.S. Food & Drug Administration (FDA). Guidance for Industry SUPAC-MR: modified release solid oral dosage forms scale-up and postapproval changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. 1997. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry. Accessed 03 March 2020."},{"key":"495_CR6","unstructured":"European Medicines Agency (EMA). Guideline On The Investigation of Bioequivalence. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 03 March 2020."},{"key":"495_CR7","unstructured":"U.S. Food & Drug Administration (FDA). Statistical approaches to establishing bioequivalence. 2001. https:\/\/www.fda.gov\/media\/70958\/download. Accessed 19 June 2020."},{"key":"495_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bcpt.12558","volume":"119","author":"I Moreno","year":"2016","unstructured":"Moreno I, Ochoa D, Rom\u00e1n M, Cabaleiro T, Abad-Santos F. Utility of pilot studies for predicting ratios and intrasubject variability in high-variability drugs. Basic Clin Pharmacol Toxicol. 2016;119:215\u201321.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"495_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1208\/s12248-019-0298-x","volume":"21","author":"T Heimbach","year":"2019","unstructured":"Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, et al. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link-a workshop summary report. AAPS J. 2019;21(2):29.","journal-title":"AAPS J"},{"key":"495_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cpt.1065","volume":"104","author":"L Fang","year":"2018","unstructured":"Fang L, Kim MJ, Li Z, Wang Y, DiLiberti CE, Au J, et al. Model-informed drug development and review for generic products: summary of FDA public workshop. Clin Pharmacol Ther. 2018;104:27\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"495_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejpb.2018.12.010","volume":"136","author":"J Butler","year":"2019","unstructured":"Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, et al. In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70\u201383.","journal-title":"Eur J Pharm Biopharm"},{"key":"495_CR12","doi-asserted-by":"publisher","unstructured":"Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner DB, Dressman J. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. Eur J Pharm Sci. 2020. https:\/\/doi.org\/10.1016\/j.ejps.2019.105170.","DOI":"10.1016\/j.ejps.2019.105170"},{"key":"495_CR13","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1098\/rsif.2011.0891","volume":"9","author":"T Sumner","year":"2012","unstructured":"Sumner T, et al. Methodology for global-sensitivity analysis of time-dependent outputs in systems biology modelling. J R Soc Interface. 2012;9:2156\u201366.","journal-title":"J R Soc Interface"},{"issue":"12","key":"495_CR14","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1016\/j.xphs.2016.08.024","volume":"105","author":"R Cristofoletti","year":"2016","unstructured":"Cristofoletti R, Dressman JB. Bridging the gap between in vitro dissolution and the time course of ibuprofen-mediating pain relief. J Pharm Sci. 2016;105(12):3658\u201367.","journal-title":"J Pharm Sci"},{"issue":"2","key":"495_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00401706.1991.10484804","volume":"33","author":"MD Morris","year":"1999","unstructured":"Morris MD. Factorial sampling plans for preliminary computational experiments. Technimetrics. 1999;33(2):161\u201374.","journal-title":"Technimetrics"},{"key":"495_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejpb.2016.06.004","volume":"105","author":"R Cristofoletti","year":"2016","unstructured":"Cristofoletti R, Dressman JB. FaSSIF-V3, but not compendial media, appropriately detects differences in the peak and extent of exposure between reference and test formulations of ibuprofen. Eur J Pharm Biopharm. 2016;105:134\u201340.","journal-title":"Eur J Pharm Biopharm"},{"key":"495_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejpb.2015.05.015","volume":"94","author":"A Fuchs","year":"2015","unstructured":"Fuchs A, Leigh M, Kloefer B, Dressman JB. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3. Eur J Pharm Biopharm. 2015;94:229\u201340.","journal-title":"Eur J Pharm Biopharm"},{"key":"495_CR18","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1021\/acs.molpharmaceut.7b00406","volume":"14","author":"SM Pathak","year":"2017","unstructured":"Pathak SM, Ruff A, Kostewicz ES, Patel N, Turner DB, Jamei M. Model-based analysis of biopharmaceutic experiments to improve mechanistic oral absorption modeling: an integrated in vitro in vivo extrapolation perspective using ketoconazole as a model drug. Mol Pharm. 2017;14:4305\u201320.","journal-title":"Mol Pharm"},{"key":"495_CR19","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1016\/j.xphs.2019.09.012","volume":"108","author":"R Cristofoletti","year":"2019","unstructured":"Cristofoletti R, Hens B, Patel N, Esteban VV, Schmidt S, Dressman J. Integrating drug- and formulation-related properties with gastrointestinal tract variability using a product-specific particle size approach: case example ibuprofen. J Pharm Sci. 2019;108:3842\u20137.","journal-title":"J Pharm Sci"},{"key":"495_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijpharm.2006.05.010","volume":"321","author":"VNP Le","year":"2006","unstructured":"Le VNP, et al. Influence of granulation and compaction on the particle size of ibuprofen--development of a size analysis method. Int J Pharm. 2006;321:72\u20137.","journal-title":"Int J Pharm"},{"key":"495_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5:211\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"495_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/bit.23321","volume":"109","author":"ME Kolewe","year":"2012","unstructured":"Kolewe ME, Roberts SC, Henson MA. A population balance equation model of aggregation dynamics in Taxus suspension cell cultures. Biotechnol Bioeng. 2012;109:472\u201382.","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"495_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/bdd.2510110311","volume":"11","author":"W Martin","year":"1990","unstructured":"Martin W, Koselowske G, T\u00f6berich H, Kerkmann T, Mangold B, Augustin J. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Dispos. 1990;11(3):265\u201378.","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"495_CR24","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos. 2014;42(9):1478\u201384.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"495_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39(2):170\u20133.","journal-title":"Drug Metab Dispos"},{"key":"495_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. 2019. https:\/\/www.R-project.org\/. Accessed 03 March 2020."},{"issue":"4","key":"495_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40268-014-0070-8","volume":"14","author":"TJ Legg","year":"2014","unstructured":"Legg TJ, Laurent AL, Leyva R, Kellstein D. Ibuprofen sodium is absorbed faster than standard ibuprofen tablets: results of two open-label, randomized, crossover pharmacokinetic studies. Drugs R D. 2014;14(4):283\u201390.","journal-title":"Drugs R D"},{"issue":"6","key":"495_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2165\/00003088-200038060-00004","volume":"38","author":"IF Troconiz","year":"2001","unstructured":"Troconiz IF, Armenteros S, Planelles MV, Benitez J, Calvos R, Dominguez R. Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet. 2001;38(6):505\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"495_CR29","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1002\/jps.24391","volume":"104","author":"K Sugano","year":"2015","unstructured":"Sugano K, Terada K. Rate- and extent-limiting factors of oral drug absorption: theory and applications. J Pharm Sci. 2015;104(9):2777\u201388.","journal-title":"J Pharm Sci"},{"key":"495_CR30","unstructured":"Blume H, Mutschler E. Bioaquivalenz, Qualitatsbewertung wirkstoffgleicher Fertigarzneimittel, Teil I\/II, Isosorbiddinitrat 6. Erg\u00a8anzungslieferung, Govi-Verlag Pharmazeutischer Verlag, Frankfurt\/Main-Eschborn; 1996."},{"key":"495_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejps.2017.12.009","volume":"115","author":"I Lozoya-Agullo","year":"2018","unstructured":"Lozoya-Agullo I, Ara\u00fajo F, Gonz\u00e1lez-\u00c1lvarez I, Merino-Sanju\u00e1n M, Gonz\u00e1lez-\u00c1lvarez M, Bermejo M, et al. PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. Eur J Pharm Sci. 2018;115:119\u201325.","journal-title":"Eur J Pharm Sci"},{"key":"495_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40261-015-0320-8","volume":"35","author":"HC Atkinson","year":"2015","unstructured":"Atkinson HC, Stanescu I, Frampton C, Salem II, Beasley CPH, Robson R. Pharmacokinetics and bioavailability of a fixed-dose combination of ibuprofen and paracetamol after intravenous and Oral administration. Clin Drug Investig. 2015;35:625\u201332.","journal-title":"Clin Drug Investig"},{"key":"495_CR33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1345\/aph.1M141","volume":"43","author":"BM Davit","year":"2009","unstructured":"Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43:1583\u201397.","journal-title":"Ann Pharmacother"},{"key":"495_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/cpt.1242","volume":"105","author":"A Mitra","year":"2019","unstructured":"Mitra A. Maximizing the role of physiologically based Oral absorption modeling in generic drug development. Clin Pharmacol Ther. 2019;105:307\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"495_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/cpt.1364","volume":"105","author":"RA Lionberger","year":"2019","unstructured":"Lionberger RA. Innovation for generic drugs: science and research under the generic drug user fee amendments of 2012. Clin Pharmacol Ther. 2019;105:878\u201385.","journal-title":"Clin Pharmacol Ther"},{"key":"495_CR36","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jcph.929","volume":"59","author":"RA Lionberger","year":"2019","unstructured":"Lionberger RA. Decision science for generic drug development and review. J Clin Pharmacol. 2019;59:1249\u201351.","journal-title":"J Clin Pharmacol"},{"key":"495_CR37","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cpt.1772","volume":"107","author":"E Manolis","year":"2020","unstructured":"Manolis E, Musuamba FT, Karlsson KE. Regulatory considerations for building an in silico clinical pharmacology backbone by 2030. Clin Pharmacol Ther. 2020;107:746\u20138. https:\/\/doi.org\/10.1002\/cpt.1772.","journal-title":"Clin Pharmacol Ther"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-020-00495-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:26:53Z","timestamp":1696570013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-020-00495-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,23]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00495-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,23]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"113"}}